Navigation Links
Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
Date:1/13/2010

Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership to provide fully integrated topical clinical phase 1 study services for trials in healthy human subjects, providing drug developers with a single source for outsourcing clinical trials.

Wareham, MA (PRWEB) January 13, 2010 -- Synomics Pharma and BioScience Laboratories, Inc. announced a formal partnership to provide fully integrated topical clinical phase 1 study services for trials in healthy human subjects, providing drug developers with a single source for outsourcing clinical trials.

Synomics Pharma’s reliable preclinical and clinical bioanalysis and analytical chemistry services, combined with BioScience Laboratories’ 18 years of experience conducting clinical trials, provides drug developers with a comprehensive outsourcing solution for topical clinical phase 1 study needs in a GCP and GLP compliant environment.

As the need for improved quality of data from clinical trials rises, drug developers are increasingly turning to United States-based contract research organizations (CROs). To ensure regulatory acceptance, pharmaceutical developers are requiring that clinical trials be conducted in strict compliance with the FDA, GCP, and GLP guidelines. For drug developers trying to bring a product to market while adhering to stringent timelines, selecting a CRO capable of conducting the clinical trial on time, on budget, and with resulting data suitable for FDA submission is critical. The partnership between Synomics Pharma and BioScience Laboratories enables an efficient single point of project management, with a full array of bioanalytical and topical clinical trial capabilities.

“Our significant experience in conducting clinical trials, combined with Synomics Pharma’s robust quality system, responsive team, and state-of-the-art bioanalysis techniques, creates an exceptional resource for outsourcing phase 1 clinical trials,” said Daryl Paulson, Ph.D., Chief Executive Officer of BioScience Laboratories.

“Synomics Pharma’s comprehensive quality management system reduces regulatory risk,” said John Pirro, Vice President and Chief Operating Officer of Synomics Pharma. “Our active involvement with the Bioanalytical Quality Standards Initiative (BQSI) for the implementation of ICH Q10 for clinical trials demonstrates our commitment to consistency and quality in clinical bioanalysis. The alliance between Synomics Pharma and BioScience Laboratories produces a versatile topical clinical phase 1 study service offering that will be highly beneficial to the industry.”

A white paper from Synomics Pharma, titled “BioAnalytical Quality Standard Initiative — Implementing ICH Q10 for Clinical Trials”, describes the BQSI, an initiative born out of the industry-wide recognition that neither the US FDA or EMEA regulation nor ICH harmonized guidelines address laboratory analysis in support of clinical trials. To download the white paper, visit http://info.synomicspharma.com/bqsi/.

Synomics Pharmaceutical Services, LLC, a global Contract Research Organization (CRO), specializes in customized preclinical and clinical bioanalytical services, stability studies, and analytical chemistry services for the pharmaceutical industry for the pharmaceutical, personal care, and allied industries. Synomics Pharma, a Smithers Group company, provides a broad portfolio of services in support of drug development and production, and its FDA-inspected quality management system is globally recognized by authorities as an industry benchmark. Smithers Group member company, SP Formulations, provides drug formulation development services in a variety of pharmaceutical dosage forms including parenterals, liquids, and semi-solids.

BioScience Laboratories, Inc. was founded in 1991 in Bozeman, MT, to provide antimicrobial product testing and result interpretation grounded in science. Today, BioScience Laboratories offers a variety of state-of-the-art laboratory services and guidance regarding federal regulatory agency requirements for the healthcare, pharmaceutical, personal care and consumer products markets.

###

Read the full story at http://www.prweb.com/releases/2010/01/prweb3439734.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
2. Genetix Pharmaceuticals' Adrenoleukodystrophy (ALD) Product Recognized As One of Science Magazine's Top 10 Scientific Breakthroughs of 2009
3. Keenan Offers New Pharmacy Discount Card Program with No Eligibility Requirements and No Cost to User
4. Penn Pharma Invests In World-Class Inventory Management System
5. Seven More Biopharmaceutical Research Companies Join PhRMA
6. CVS/pharmacy and MinuteClinic to Provide H1N1 Vaccines in 8 New States
7. PharmaSmart International, Inc and AstraZeneca Canada Enter Into Strategic Partnership to Elevate Pharmacy Based Hypertension Management
8. Pharmacists improve care of diabetics while cutting costs, UB research shows
9. 5,000 Web Sites Selling Prescription Drugs Outside of Pharmacy Laws and Practice Standards
10. Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans
11. CVS/pharmacy and MinuteClinic Now Providing H1N1 Vaccinations in Arizona
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services 
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric ... Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to his ... to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary ... to the company,s board of directors: ... Partners. Mr. Gabrieli will serve as chairman of the board ... former chief commercial officer of Forest Laboratories. ... Biolink Partners. "We are excited to ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
Breaking Medicine Technology: